Avinger Inc. (AVGR) Sees Strong Trading Volume
Avinger Inc. (NASDAQ:AVGR) shares saw an uptick in trading volume on Friday . 559,820 shares were traded during mid-day trading, an increase of 47% from the previous session’s volume of 382,025 shares.The stock last traded at $3.67 and had previously closed at $3.75.
A number of brokerages have issued reports on AVGR. Zacks Investment Research raised Avinger from a “sell” rating to a “hold” rating in a research note on Thursday, May 19th. BTIG Research reaffirmed a “buy” rating and set a $18.00 price target on shares of Avinger in a research note on Friday, July 15th. Finally, Canaccord Genuity reaffirmed a “buy” rating on shares of Avinger in a research note on Tuesday, July 12th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $18.75.
The firm has a 50 day moving average of $7.46 and a 200-day moving average of $10.98. The company’s market capitalization is $47.00 million.
Avinger (NASDAQ:AVGR) last released its quarterly earnings data on Monday, August 1st. The medical device company reported ($1.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.09. The company had revenue of $4.70 million for the quarter, compared to analyst estimates of $3.05 million. On average, equities research analysts anticipate that Avinger Inc. will post ($4.18) earnings per share for the current year.
Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.